Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Lymphoma
Related studies linked through entity extraction aliases.
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Multi-center, Prospective, Single-blind, Controlled Trial Comparing Diagnostic Value of Different EUS-FNA Techniques
- Status
- UNKNOWN
- Phase
- NA
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE3
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Managed Access Programs for CTL019, Tisagenlecleucel
- Status
- AVAILABLE
- Phase
- N/A
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Spa Therapy for Upper or Lower Limb Lymphoedema
- Status
- RECRUITING
- Phase
- NA
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE1
SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart
- Status
- COMPLETED
- Phase
- NA
Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and Lymphoma
- Status
- RECRUITING
- Phase
- NA
WB-EMS and Nutrition in Patients With Hematological Malignancies
- Status
- UNKNOWN
- Phase
- NA
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
- Status
- UNKNOWN
- Phase
- PHASE2
Geriatric Communication Skills Training Program for Oncology Clinicians
- Status
- COMPLETED
- Phase
- NA
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1